drugset / Trial / NCT06201793
Minocyclin in Ulcerative Colitis as Added on Therapy
Phase 2
Completed
46 enrolled
Mostafa Bahaa
Amira Fawzy Mohamed Mashaly, Clinical Pharmacy Demonstrator, Faculty of Pharmacy- Horus University · collabMounir Hussein Bahgat Internal Medicine Department Mansoura University · collabTanta University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Ulcerative colitis (UC) is considered a subcategory of inflammatory bowel disease and the exact cause of ulcerative colitis remains undetermined. the condition appears to be related dysregulated immune response and consequent activation of inflammatory cascades, which are often affected by genetic susceptibility and environmental factors, and 20% to 40% of patients with UC also exhibit extraintestinal manifestations involving the joints, skin, eyes, or hepatobiliary tract
Timeline
- Start
- 2024-01-22
- Primary completion
- 2025-01-20
- Completion
- 2025-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Minocycline | Small molecule | 100 mg | — |
| Comparator | Mesalamine | Small molecule | 1 g | — |